Items where authors include "Van der Heijde, D"

Export as [feed] Atom [feed] RSS
Number of items: 11.

Article

Weinblatt, ME, Bingham, CO, Burmester, G-R et al. (9 more authors) (2017) A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis and Rheumatology, 69 (10). pp. 1937-1948. ISSN 2326-5191

Smolen, JS, Landewé, R, Bijlsma, J et al. (46 more authors) (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 76 (6). pp. 960-977. ISSN 0003-4967

Dougados, M, Van der Heijde, D, Chen, YC et al. (11 more authors) (2017) Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study. Annals of the Rheumatic Diseases, 76 (1). pp. 88-95. ISSN 0003-4967

Emery, P, Bingham III, CO, Burmester, GR et al. (11 more authors) (2017) Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. Annals of the Rheumatic Diseases, 76 (1). pp. 96-104. ISSN 0003-4967

Lambert, RGW, Bakker, PAC, Van der Heijde, D et al. (19 more authors) (2016) Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: Update by the ASAS MRI working group. Annals of the Rheumatic Diseases, 75 (11). pp. 1958-1963. ISSN 0003-4967

Van der Heijde, D, Landewé, RB, Mease, PJ et al. (6 more authors) (2016) Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis. Arthritis & Rheumatology, 68 (8). pp. 1914-1921. ISSN 2326-5191

Sepriano, A, Landewé, R, Van der Heijde, D et al. (23 more authors) (2016) Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. Annals of the Rheumatic Diseases, 75 (6). pp. 1034-1042. ISSN 0003-4967

Moltó, A, Etcheto, A, Van der Heijde, D et al. (23 more authors) (2016) Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Annals of the Rheumatic Diseases, 75 (6). pp. 1016-1023. ISSN 0003-4967

Buch, MH orcid.org/0000-0002-8962-5642, Silva-Fernandez, L, Carmona, L et al. (18 more authors) (2015) Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. Annals of the Rheumatic Diseases, 74 (6). pp. 963-969. ISSN 0003-4967

Conference or Workshop Item

Poddubnyy, D, Mease, PJ, Van den Bosch, F et al. (9 more authors) (2020) AB0824 WHICH PARAMETERS ARE RELEVANT IN THE IDENTIFYING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS? – RESULTS OF A SURVEY AMONG ASAS AND GRAPPA MEMBERS. In: EULAR 2020, 03-06 Jun 2020, Online.

Helliwell, P, Gladman, DD, Poddubnyy, D et al. (13 more authors) (2020) OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. In: EULAR 2020, 03-06 Jun 2020, Online.

This list was generated on Sun Apr 21 22:04:44 2024 BST.